AgingResearch.NewsJoin free

Anti-acbp monoclonal antibody

Intervention

1 paper4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: Agence Nationale de la Recherche and 7 more
  • Humans1

Outcomes

4

Dysregulation of cardioprotective protein mRNAs

downin mice1

1 study

  1. Anti-acbp monoclonal antibody decreases dysregulation of cardioprotective protein mRNAs in mice.

    “In cardiomyocytes, doxorubicin caused an anti-ACBP-reversible dysregulation of mRNAs coding for cardioprotective proteins involved in autophagy, fatty acid oxidation, mitochondrial homeostasis, and oxidative phosphorylation.”

    Animalsdoxorubicin exposurecardiomyocyte

    Acyl-CoA-binding protein as a driver of pathological aging

    Proceedings of the National Academy of Sciences of the United States of America7 Jul 2025

More on Dysregulation of cardioprotective protein mRNAs

Cellular senescence

downin mice1

1 study

  1. Anti-acbp monoclonal antibody prevents cellular senescence in mice.

    “Moreover, administration of anti-ACBP mAb prevented natural and doxorubicin-accelerated cardiomyocyte senescence.”

    Animalsnatural and doxorubicin-accelerated senescencecardiomyocyte

    Acyl-CoA-binding protein as a driver of pathological aging

    Proceedings of the National Academy of Sciences of the United States of America7 Jul 2025

More on Cellular senescence

Histopathological and functional signs of kidney failure

downin mice1

1 study

  1. Anti-acbp monoclonal antibody decreases histopathological and functional signs of kidney failure in mice.

    “In a mouse model of chronic kidney injury induced by cisplatin, anti-ACBP mAb administration counteracted both histopathological and functional signs of organ failure.”

    Animalscisplatin-induced chronic kidney injurykidney

    Acyl-CoA-binding protein as a driver of pathological aging

    Proceedings of the National Academy of Sciences of the United States of America7 Jul 2025

Healthspan

upin mice1

1 study

  1. Anti-acbp monoclonal antibody improves healthspan in mice.

    “ACBP neutralization by means of a monoclonal antibody (mAb) improved health span in a strain of progeroid mice.”

    Animalsprogeroid mice

    Acyl-CoA-binding protein as a driver of pathological aging

    Proceedings of the National Academy of Sciences of the United States of America7 Jul 2025

Latest

Related